Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 11/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 6/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.49 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.49 |
| ▸ | TMPRSS6 | Q8IU80 | 3/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6380991 | 0.88 | POLB (0.58) | POLB | |
| SCHEMBL4414766 | 0.83 | F7 (0.57) | PRSS1ITGB3ITGA2BF2F10 | |
| SCHEMBL7338663 | 0.83 | TSHR (0.65) | POLB | |
| SCHEMBL11815924 | 0.83 | POLB (0.60) | POLB | |
| SCHEMBL4035568 | 0.81 | POLB (0.62) | POLB | |
| SCHEMBL16166407 | 0.81 | PRSS1 (0.46) | PRSS1ITGB3ITGA2BF2PRSS2 | |
| SCHEMBL219868 | 0.81 | POLB (0.61) | POLB | |
| SCHEMBL4035087 | 0.80 | POLB (0.65) | POLB | |
| Hydrochloric Acid SCHEMBL10499404 | 0.80 | POLB (0.60) | POLB | |
| SCHEMBL1372423 | 0.79 | POLB (0.63) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978750-B1 | \"SYNTHESIS OF DABIGATRAN\ | USV PRIVATE LTD (IN) | 2020-03-04 | — | — | EP | disclosed |
| US-9688657-B2 | Synthesis of dabigatran | USV PRIVATE LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-9688657-B2 | Synthesis of dabigatran | USV PRIVATE LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-9688657-B2 | Synthesis of dabigatran | USV PRIVATE LIMITED (IN) | 2017-06-27 | — | — | US | disclosed |
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | USV PRIVATE LIMITED (IN) | 2016-03-03 | — | — | US | disclosed |
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | USV PRIVATE LIMITED (IN) | 2016-03-03 | — | — | US | disclosed |
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | USV PRIVATE LIMITED (IN) | 2016-03-03 | — | — | US | disclosed |
| EP-2978750-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV Limited (IN) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014167577-A2 | \"SYNTHESIS OF DABIGATRAN\ | USV LIMITED (IN) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060248-A1 | SYNTHESIS OF DABIGATRAN | ESD, F2, PROC | POLB 2992/4885PRSS1 347/4885ITGB3 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.